Group 1 - The core viewpoint of the news is that Nona Bio, a wholly-owned subsidiary of Harbour BioMed, has entered into an evaluation and licensing agreement with Umoja Biopharma to advance the development of multiple in vivo CAR-T cell products [1] - The agreement signifies a deepening of the strategic partnership established between the two companies in September 2024 [1] - Under the terms of the agreement, Nona Bio will receive an upfront payment, potential option payments, and milestone payments related to the discovery and development of collaborative projects [1] Group 2 - Umoja Biopharma is a clinical-stage biotechnology company focused on developing more accessible and effective in vivo CAR-T cell therapies for oncology and autoimmune diseases [2] - The VivoVec in vivo gene delivery technology from Umoja Biopharma enhances the patient's immune system's ability to combat diseases [2] - The company operates an advanced slow virus vector development and manufacturing facility located in Louisville, Colorado, which supports its core technology [2]
和铂医药-B(02142)与UMOJA BIOPHARMA订立评估与授权协议